What is CVRx?
Headquartered in Minneapolis, Minnesota, CVRx, Inc. is a commercial-stage medical device innovator focused on the development and manufacturing of neuromodulation therapies. Its flagship product, Barostim, represents a significant advancement in the treatment of heart failure with reduced ejection fraction. By utilizing the body's natural baroreflex, the device provides a unique therapeutic approach for patients who have limited options with traditional pharmacological interventions. The company maintains a global footprint, utilizing a direct sales force and strategic distribution partnerships to reach key markets in the United States and Germany.
How much funding has CVRx raised?
CVRx has raised a total of $478.4M across 11 funding rounds:
Series C
$30.1M
Series D
$65M
Series A
$84M
Private Equity
$29.6M
Series F
$12M
Debt
$15M
Multiple Rounds
$170.7M
Other Financing Round
$50M
Series C (2006): $30.1M, investors not publicly disclosed
Series D (2007): $65M supported by Kearny Venture Partners and InterWest Partners
Series A (2008): $84M featuring InterWest Partners, Frazier Healthcare Partners, and SightLine Partners
Private Equity (2013): $29.6M backed by SightLine Partners and Sterling Capital Management
Series F (2013): $12M with participation from Ysios Capital and DaVita
Debt (2014): $15M led by Silicon Valley Bank
Private Equity (2016): $57.7M, investors not publicly disclosed
Debt (2016): $20M featuring Oxford Finance
Series G (2016): $93M backed by JJDC, Gilde Healthcare, Action Potential Venture Capital, New Enterprise Associates, Ysios Capital, and Windham Venture Partners
Other Financing Round (2020): $50M with participation from Hatteras Venture Partners, Vensana Capital Management LLC, Strategic Healthcare Investment Partners, and Venrock Healthcare Capital Partners
Key Investors in CVRx
JJDC
Johnson & Johnson is a global healthcare company that develops pharmaceuticals and medical technologies, providing innovative medicines and devices across multiple therapeutic areas.
Action Potential Venture Capital
A prominent medical technology venture capital firm established by GSK, focusing on the development of bioelectronic medicines and therapies targeting the nervous system.
Gilde Healthcare
A specialized healthcare investment firm managing multiple fund strategies, focusing on businesses that enable better care at lower costs through innovation.
What's next for CVRx?
With the support of its recent strategic financing, CVRx is positioned to accelerate the adoption of its neuromodulation platform. The company's strategic roadmap likely involves expanding its commercial reach and deepening its clinical evidence base to support broader physician adoption. As the firm navigates the complexities of the medical device landscape, the focus remains on scaling operations and maintaining its competitive edge in the bioelectronic medicine space. Future growth will likely be driven by continued investment in product innovation and the expansion of its international distribution network to capture a larger share of the cardiovascular care market.
See full CVRx company page
